Rchr
J-GLOBAL ID:200901039006528351
Update date: Apr. 28, 2022
Naiki Kayoko
Naiki Kayoko
Research theme for competitive and other funds (4):
2004 - 現在 肝線維化,肝再生の機序と治療学の確立に関する研究
2004 - 現在 肝疾患の病態を規定する宿主要因の検討:Osteopontin promoter SNPsの解析
2004 - 現在 肝炎劇症化の機序と治療法の開発に関する研究:Osteopontinトランスジェニックマウスの確立とこれを用いた検討
2004 - 現在 わが国固有のE型肝炎に関する分子ウイルス学的研究
Papers (3):
Uchida Yoshihito, Inao Mie, Tsuji syouhei, Uemura Hayato, Kouyama Jun-Ichi, Naiki Kayoko, Sugawara Kayoko, Nakao Masamitsu, Nakayama Nobuaki, Imai Yukinori, et al. Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis. Hepatology Research. 2020. 50. 12. 13555-1364
Uchida Yoshihito, Tsuji syouhei, Uemura Hayato, Kouyama Jun-Ichi, Naiki Kayoko, Sugawara Kayoko, Nakao Masamitsu, Inao Mie, Nakayama Nobuaki, Imai Yukinori, et al. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis. Hepatology Research. 2020. 50. 11. 1264-1274
Tsuji syouhei, Uchida Yoshihito, Uemura Hayato, Kouyama Jun-Ichi, Naiki Kayoko, Nakao Masamitsu, Motoya Daisuke, Sugawara Kayoko, Nakayama Nobuaki, Imai Yukinori, et al. Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatology Research. 2020. 50. 4. 512-523
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM